SI2968129T1 - Proti zlorabi odporna kapsula - Google Patents
Proti zlorabi odporna kapsulaInfo
- Publication number
- SI2968129T1 SI2968129T1 SI201430988T SI201430988T SI2968129T1 SI 2968129 T1 SI2968129 T1 SI 2968129T1 SI 201430988 T SI201430988 T SI 201430988T SI 201430988 T SI201430988 T SI 201430988T SI 2968129 T1 SI2968129 T1 SI 2968129T1
- Authority
- SI
- Slovenia
- Prior art keywords
- abuse resistant
- resistant capsule
- capsule
- abuse
- resistant
- Prior art date
Links
Classifications
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K9/00—Medicinal preparations characterised by special physical form
- A61K9/48—Preparations in capsules, e.g. of gelatin, of chocolate
- A61K9/4841—Filling excipients; Inactive ingredients
- A61K9/4866—Organic macromolecular compounds
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K31/00—Medicinal preparations containing organic active ingredients
- A61K31/13—Amines
- A61K31/135—Amines having aromatic rings, e.g. ketamine, nortriptyline
- A61K31/137—Arylalkylamines, e.g. amphetamine, epinephrine, salbutamol, ephedrine or methadone
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K31/00—Medicinal preparations containing organic active ingredients
- A61K31/185—Acids; Anhydrides, halides or salts thereof, e.g. sulfur acids, imidic, hydrazonic or hydroximic acids
- A61K31/19—Carboxylic acids, e.g. valproic acid
- A61K31/195—Carboxylic acids, e.g. valproic acid having an amino group
- A61K31/196—Carboxylic acids, e.g. valproic acid having an amino group the amino group being directly attached to a ring, e.g. anthranilic acid, mefenamic acid, diclofenac, chlorambucil
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K31/00—Medicinal preparations containing organic active ingredients
- A61K31/33—Heterocyclic compounds
- A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
- A61K31/435—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with one nitrogen as the only ring hetero atom
- A61K31/47—Quinolines; Isoquinolines
- A61K31/485—Morphinan derivatives, e.g. morphine, codeine
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K47/00—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient
- A61K47/06—Organic compounds, e.g. natural or synthetic hydrocarbons, polyolefins, mineral oil, petrolatum or ozokerite
- A61K47/08—Organic compounds, e.g. natural or synthetic hydrocarbons, polyolefins, mineral oil, petrolatum or ozokerite containing oxygen, e.g. ethers, acetals, ketones, quinones, aldehydes, peroxides
- A61K47/14—Esters of carboxylic acids, e.g. fatty acid monoglycerides, medium-chain triglycerides, parabens or PEG fatty acid esters
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K47/00—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient
- A61K47/06—Organic compounds, e.g. natural or synthetic hydrocarbons, polyolefins, mineral oil, petrolatum or ozokerite
- A61K47/26—Carbohydrates, e.g. sugar alcohols, amino sugars, nucleic acids, mono-, di- or oligo-saccharides; Derivatives thereof, e.g. polysorbates, sorbitan fatty acid esters or glycyrrhizin
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K47/00—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient
- A61K47/30—Macromolecular organic or inorganic compounds, e.g. inorganic polyphosphates
- A61K47/36—Polysaccharides; Derivatives thereof, e.g. gums, starch, alginate, dextrin, hyaluronic acid, chitosan, inulin, agar or pectin
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K47/00—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient
- A61K47/44—Oils, fats or waxes according to two or more groups of A61K47/02-A61K47/42; Natural or modified natural oils, fats or waxes, e.g. castor oil, polyethoxylated castor oil, montan wax, lignite, shellac, rosin, beeswax or lanolin
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K9/00—Medicinal preparations characterised by special physical form
- A61K9/06—Ointments; Bases therefor; Other semi-solid forms, e.g. creams, sticks, gels
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K9/00—Medicinal preparations characterised by special physical form
- A61K9/08—Solutions
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K9/00—Medicinal preparations characterised by special physical form
- A61K9/10—Dispersions; Emulsions
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K9/00—Medicinal preparations characterised by special physical form
- A61K9/48—Preparations in capsules, e.g. of gelatin, of chocolate
- A61K9/4816—Wall or shell material
- A61K9/4825—Proteins, e.g. gelatin
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K9/00—Medicinal preparations characterised by special physical form
- A61K9/48—Preparations in capsules, e.g. of gelatin, of chocolate
- A61K9/4841—Filling excipients; Inactive ingredients
- A61K9/4858—Organic compounds
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K9/00—Medicinal preparations characterised by special physical form
- A61K9/48—Preparations in capsules, e.g. of gelatin, of chocolate
- A61K9/4841—Filling excipients; Inactive ingredients
- A61K9/4875—Compounds of unknown constitution, e.g. material from plants or animals
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K9/00—Medicinal preparations characterised by special physical form
- A61K9/48—Preparations in capsules, e.g. of gelatin, of chocolate
- A61K9/4891—Coated capsules; Multilayered drug free capsule shells
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P23/00—Anaesthetics
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P25/00—Drugs for disorders of the nervous system
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P25/00—Drugs for disorders of the nervous system
- A61P25/04—Centrally acting analgesics, e.g. opioids
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P25/00—Drugs for disorders of the nervous system
- A61P25/18—Antipsychotics, i.e. neuroleptics; Drugs for mania or schizophrenia
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P25/00—Drugs for disorders of the nervous system
- A61P25/20—Hypnotics; Sedatives
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P25/00—Drugs for disorders of the nervous system
- A61P25/22—Anxiolytics
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P25/00—Drugs for disorders of the nervous system
- A61P25/24—Antidepressants
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P25/00—Drugs for disorders of the nervous system
- A61P25/26—Psychostimulants, e.g. nicotine, cocaine
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P25/00—Drugs for disorders of the nervous system
- A61P25/30—Drugs for disorders of the nervous system for treating abuse or dependence
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P25/00—Drugs for disorders of the nervous system
- A61P25/30—Drugs for disorders of the nervous system for treating abuse or dependence
- A61P25/36—Opioid-abuse
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K9/00—Medicinal preparations characterised by special physical form
- A61K9/48—Preparations in capsules, e.g. of gelatin, of chocolate
- A61K9/4841—Filling excipients; Inactive ingredients
- A61K9/485—Inorganic compounds
Landscapes
- Health & Medical Sciences (AREA)
- Chemical & Material Sciences (AREA)
- Life Sciences & Earth Sciences (AREA)
- Pharmacology & Pharmacy (AREA)
- Veterinary Medicine (AREA)
- Public Health (AREA)
- General Health & Medical Sciences (AREA)
- Animal Behavior & Ethology (AREA)
- Medicinal Chemistry (AREA)
- Epidemiology (AREA)
- Engineering & Computer Science (AREA)
- Chemical Kinetics & Catalysis (AREA)
- General Chemical & Material Sciences (AREA)
- Bioinformatics & Cheminformatics (AREA)
- Organic Chemistry (AREA)
- Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
- Neurosurgery (AREA)
- Neurology (AREA)
- Biomedical Technology (AREA)
- Oil, Petroleum & Natural Gas (AREA)
- Psychiatry (AREA)
- Emergency Medicine (AREA)
- Addiction (AREA)
- Zoology (AREA)
- Botany (AREA)
- Inorganic Chemistry (AREA)
- Biochemistry (AREA)
- Molecular Biology (AREA)
- Dispersion Chemistry (AREA)
- Pain & Pain Management (AREA)
- Anesthesiology (AREA)
- Medicinal Preparation (AREA)
- Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
- Acyclic And Carbocyclic Compounds In Medicinal Compositions (AREA)
- Medicines That Contain Protein Lipid Enzymes And Other Medicines (AREA)
Applications Claiming Priority (4)
| Application Number | Priority Date | Filing Date | Title |
|---|---|---|---|
| US201361794714P | 2013-03-15 | 2013-03-15 | |
| US14/204,259 US10420729B2 (en) | 2013-03-15 | 2014-03-11 | Abuse resistant capsule |
| PCT/EP2014/055045 WO2014140231A1 (en) | 2013-03-15 | 2014-03-14 | Abuse resistant capsule |
| EP14711201.5A EP2968129B1 (en) | 2013-03-15 | 2014-03-14 | Abuse resistant capsule |
Publications (1)
| Publication Number | Publication Date |
|---|---|
| SI2968129T1 true SI2968129T1 (sl) | 2019-01-31 |
Family
ID=51528060
Family Applications (1)
| Application Number | Title | Priority Date | Filing Date |
|---|---|---|---|
| SI201430988T SI2968129T1 (sl) | 2013-03-15 | 2014-03-14 | Proti zlorabi odporna kapsula |
Country Status (15)
| Country | Link |
|---|---|
| US (4) | US10420729B2 (sl) |
| EP (3) | EP2968129B1 (sl) |
| JP (4) | JP6395734B2 (sl) |
| CN (2) | CN105358132B (sl) |
| AR (1) | AR095343A1 (sl) |
| AU (3) | AU2014230481B2 (sl) |
| CA (1) | CA2902501C (sl) |
| CY (1) | CY1120959T1 (sl) |
| DK (1) | DK2968129T3 (sl) |
| ES (1) | ES2700517T3 (sl) |
| HU (1) | HUE040530T2 (sl) |
| MX (2) | MX2015012742A (sl) |
| PT (1) | PT2968129T (sl) |
| SI (1) | SI2968129T1 (sl) |
| WO (1) | WO2014140231A1 (sl) |
Families Citing this family (31)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| US7776314B2 (en) | 2002-06-17 | 2010-08-17 | Grunenthal Gmbh | Abuse-proofed dosage system |
| DE10361596A1 (de) | 2003-12-24 | 2005-09-29 | Grünenthal GmbH | Verfahren zur Herstellung einer gegen Missbrauch gesicherten Darreichungsform |
| DE102005005446A1 (de) | 2005-02-04 | 2006-08-10 | Grünenthal GmbH | Bruchfeste Darreichungsformen mit retardierter Freisetzung |
| CA2569958C (en) | 2004-06-12 | 2016-03-22 | Jane C. Hirsh | Abuse-deterrent drug formulations |
| DE102004032049A1 (de) | 2004-07-01 | 2006-01-19 | Grünenthal GmbH | Gegen Missbrauch gesicherte, orale Darreichungsform |
| DE102005005449A1 (de) | 2005-02-04 | 2006-08-10 | Grünenthal GmbH | Verfahren zur Herstellung einer gegen Missbrauch gesicherten Darreichungsform |
| ES2560210T3 (es) | 2009-07-22 | 2016-02-17 | Grünenthal GmbH | Forma de dosificación resistente a la manipulación para opiádes sensibles a la oxidación |
| US10668060B2 (en) | 2009-12-10 | 2020-06-02 | Collegium Pharmaceutical, Inc. | Tamper-resistant pharmaceutical compositions of opioids and other drugs |
| RU2604676C2 (ru) | 2010-09-02 | 2016-12-10 | Грюненталь Гмбх | Устойчивая к разрушению лекарственная форма, содержащая неорганическую соль |
| LT2736495T (lt) | 2011-07-29 | 2017-11-10 | Grünenthal GmbH | Sugadinimui atspari tabletė, pasižyminti greitu vaisto atpalaidavimu |
| CN103857386A (zh) | 2011-07-29 | 2014-06-11 | 格吕伦塔尔有限公司 | 提供药物立即释放的抗破碎片剂 |
| CA2868142A1 (en) | 2012-04-18 | 2013-10-24 | Grunenthal Gmbh | Tamper resistant and dose-dumping resistant pharmaceutical dosage form |
| US10420729B2 (en) | 2013-03-15 | 2019-09-24 | R.P. Scherer Technologies, Llc | Abuse resistant capsule |
| CN105682643B (zh) | 2013-07-12 | 2019-12-13 | 格吕伦塔尔有限公司 | 含有乙烯-醋酸乙烯酯聚合物的防篡改剂型 |
| AU2014356581C1 (en) | 2013-11-26 | 2020-05-28 | Grunenthal Gmbh | Preparation of a powdery pharmaceutical composition by means of cryo-milling |
| US10744131B2 (en) * | 2013-12-31 | 2020-08-18 | Kashiv Biosciences, Llc | Abuse-resistant drug formulations |
| EP3142646A1 (en) * | 2014-05-12 | 2017-03-22 | Grünenthal GmbH | Tamper resistant immediate release capsule formulation comprising tapentadol |
| EP3291872A4 (en) | 2015-05-06 | 2019-02-13 | SynAgile Corporation | PHARMACEUTICAL SUSPENSIONS WITH ACTIVE SUBSTANCES, DEVICES FOR THEIR ADMINISTRATION AND METHOD FOR THEIR USE |
| EP3346991A1 (en) | 2015-09-10 | 2018-07-18 | Grünenthal GmbH | Protecting oral overdose with abuse deterrent immediate release formulations |
| EP3349853B1 (en) | 2015-09-15 | 2023-12-20 | Praxis Bioresearch, LLC | Prodrugs of fencamfamine |
| US20170312226A1 (en) * | 2016-04-28 | 2017-11-02 | Ascent Pharmaceuticals, Inc. | Pharmaceutical dosage forms |
| WO2017222575A1 (en) | 2016-06-23 | 2017-12-28 | Collegium Pharmaceutical, Inc. | Process of making more stable abuse-deterrent oral formulations |
| CA3039920A1 (en) * | 2016-10-10 | 2018-04-19 | Rhodes Pharmaceuticals L.P. | Pharmaceutical resinate compositions and methods of making and using thereof |
| US9931303B1 (en) * | 2017-02-06 | 2018-04-03 | Alcobra Ltd. | Abuse deterrent formulations of amphetamine |
| EP3473246A1 (en) | 2017-10-19 | 2019-04-24 | Capsugel Belgium NV | Immediate release abuse deterrent formulations |
| MX2020008813A (es) * | 2018-02-26 | 2020-09-28 | Scherer Technologies Llc R P | Forma de dosificacion farmaceutica para una emulsion de simeticona y loperamida. |
| GB201809976D0 (en) * | 2018-06-18 | 2018-08-01 | Neurocentrx Pharma Ltd | Novel formulations |
| GB201904767D0 (en) | 2019-04-04 | 2019-05-22 | Orexo Ab | New pharmaceutical compositions |
| CN110483669A (zh) * | 2019-08-13 | 2019-11-22 | 天津大学 | 一种基于二烯丙基丙二酰脲的聚合物及其制备方法 |
| KR20230165280A (ko) * | 2021-04-01 | 2023-12-05 | 알.피.쉐러 테크놀러지즈 엘엘씨 | 제약 제제에서 음이온 킬레이트화제로서의 인지질 |
| US20230159441A1 (en) * | 2021-09-29 | 2023-05-25 | Ensysce Biosciences Inc. | Enzyme-cleavable methadone prodrugs and methods of use thereof |
Family Cites Families (43)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| GB8926612D0 (en) | 1989-11-24 | 1990-01-17 | Erba Farmitalia | Pharmaceutical compositions |
| US20030118641A1 (en) * | 2000-07-27 | 2003-06-26 | Roxane Laboratories, Inc. | Abuse-resistant sustained-release opioid formulation |
| US6340471B1 (en) | 1999-12-30 | 2002-01-22 | Alvin Kershman | Method for preparing solid delivery system for encapsulated and non-encapsulated pharmaceuticals |
| US6541025B1 (en) | 1999-12-30 | 2003-04-01 | Shear/Kershman Laboratories, Inc. | Method for preparing solid delivery system for encapsulated and non-encapsulated pharmaceuticals |
| US6509040B1 (en) | 2001-06-22 | 2003-01-21 | R.P. Scherer Corporation | Fast dispersing dosage forms essentially free of mammalian gelatin |
| US7842307B2 (en) | 2001-08-06 | 2010-11-30 | Purdue Pharma L.P. | Pharmaceutical formulation containing opioid agonist, opioid antagonist and gelling agent |
| KR20040025741A (ko) | 2001-08-06 | 2004-03-25 | 유로-셀티크 소시에떼 아노뉨 | 오피오이드 남용을 방지하기 위한 조성물 및 방법 |
| US20030059397A1 (en) | 2001-09-17 | 2003-03-27 | Lyn Hughes | Dosage forms |
| US7776314B2 (en) | 2002-06-17 | 2010-08-17 | Grunenthal Gmbh | Abuse-proofed dosage system |
| US7399488B2 (en) | 2002-07-05 | 2008-07-15 | Collegium Pharmaceutical, Inc. | Abuse-deterrent pharmaceutical compositions of opiods and other drugs |
| US20050191244A1 (en) * | 2002-10-25 | 2005-09-01 | Gruenenthal Gmbh | Abuse-resistant pharmaceutical dosage form |
| MXPA05009757A (es) | 2003-03-13 | 2005-12-05 | Controlled Chemicals Inc | Conjugados de oxicodona con menor potencial de abuso y duracion de accion extendida. |
| US7201920B2 (en) | 2003-11-26 | 2007-04-10 | Acura Pharmaceuticals, Inc. | Methods and compositions for deterring abuse of opioid containing dosage forms |
| US20050271594A1 (en) | 2004-06-04 | 2005-12-08 | Groenewoud Pieter J | Abuse resistent pharmaceutical composition |
| ITMI20041317A1 (it) | 2004-06-30 | 2004-09-30 | Ibsa Inst Biochimique Sa | Formulazioni farmaceutiche per la somministrazione sicura di farmaci utilizzati nel trattamento della tossicodipendenza e procedimento per il loro ottenimento |
| GB0506982D0 (en) | 2005-04-06 | 2005-05-11 | Mw Encap Ltd | Abuse resistant capsules |
| US8252326B2 (en) | 2005-06-01 | 2012-08-28 | Catalent Australia Pty Ltd. | Self-microemulsifying dosage forms of low solubility active ingredients such as co-enzyme Q10 |
| JP5406529B2 (ja) * | 2005-10-26 | 2014-02-05 | バナー ファーマキャプス， インコーポレイテッド | カプセル充墳物としての親油性ベヒクルに基づく二重制御された放出マトリクスシステム |
| EP1959935A2 (en) * | 2005-10-26 | 2008-08-27 | Banner Pharmacaps Inc. | Hydrophilic vehicle-based dual controlled release matrix system as capsule fill |
| WO2007087452A2 (en) | 2006-01-27 | 2007-08-02 | Theraquest Biosciences, Llc | Abuse resistant and extended release formulations and method of use thereof |
| US9125833B2 (en) | 2005-11-02 | 2015-09-08 | Relmada Therapeutics, Inc. | Multimodal abuse resistant and extended release opioid formulations |
| US9265724B2 (en) | 2005-11-07 | 2016-02-23 | Ram B. Murty | Oral dosage form of tetrahydrocannabinol and a method of avoiding and/or suppressing hepatic first pass metabolism via targeted chylomicron/lipoprotein delivery |
| US20080027011A1 (en) * | 2005-12-20 | 2008-01-31 | Hassan Nached | Homogeneous paste and gel formulations |
| BRPI0709606B8 (pt) | 2006-03-16 | 2021-05-25 | Tris Pharma Inc | suspensão líquida administrável oralmente com características de liberação modificada |
| US10960077B2 (en) | 2006-05-12 | 2021-03-30 | Intellipharmaceutics Corp. | Abuse and alcohol resistant drug composition |
| US20070281065A1 (en) | 2006-06-06 | 2007-12-06 | Modliszewski James J | Kappa-2 carrageenan composition and products made therefrom |
| US8202542B1 (en) | 2007-05-31 | 2012-06-19 | Tris Pharma | Abuse resistant opioid drug-ion exchange resin complexes having hybrid coatings |
| ES2612032T3 (es) | 2007-06-04 | 2017-05-11 | Shear/Kershman Laboratories, Inc. | Formas farmacéuticas orales basadas en lípidos inviolables para agonistas opiáceos |
| US8741918B2 (en) * | 2007-06-21 | 2014-06-03 | Veroscience Llc | Parenteral formulations of dopamine agonists |
| AU2008335809A1 (en) | 2007-12-06 | 2009-06-18 | Durect Corporation | Methods useful for the treatment of pain, arthritic conditions, or inflammation associated with a chronic condition |
| WO2009114118A2 (en) | 2008-03-08 | 2009-09-17 | Theraquest Biosciences, Inc. | Oral pharmaceutical compositions of buprenorphine and method of use |
| US8420700B1 (en) | 2008-06-04 | 2013-04-16 | James M. Bausch | Tamper resistant lipid-based oral dosage form for sympathomimetic amines |
| WO2010044842A1 (en) | 2008-10-16 | 2010-04-22 | University Of Tennessee Research Foundation | Tamper resistant oral dosage forms containing an embolizing agent |
| FR2939542B1 (fr) | 2008-12-04 | 2012-08-03 | Advanced Track & Trace | Procede et dispositif de protection d'un recipient et etiquette pour leur mise en oeuvre |
| PL2379111T3 (pl) | 2008-12-12 | 2013-08-30 | Paladin Labs Inc | Preparaty leków narkotycznych o obniżonym potencjale uzależniającym |
| EP2448406B1 (en) | 2009-02-26 | 2016-04-20 | Relmada Therapeutics, Inc. | Extended release oral pharmaceutical compositions of 3-hydroxy-n-methylmorphinan and method of use |
| BRPI1009121A2 (pt) * | 2009-03-04 | 2018-06-19 | Orexo Ab | formulações resistentes a abuso |
| EP2408436B1 (en) | 2009-03-18 | 2017-02-22 | Evonik Röhm GmbH | Controlled release pharmaceutical composition with resistance against the influence of ethanol employing a coating comprising neutral vinyl polymers and excipients |
| US9125867B2 (en) * | 2010-02-24 | 2015-09-08 | Invincible Biotechnology | Diversion- and/or abuse-resistant compositions and methods for making the same |
| WO2012007159A2 (en) * | 2010-07-14 | 2012-01-19 | Grünenthal GmbH | Novel gastro-retentive dosage forms |
| US20120171277A1 (en) | 2011-01-03 | 2012-07-05 | Royds Robert B | Abuse resistant transdermal drug delivery patch including a release-enhanced antagonist |
| EP2726065A4 (en) | 2011-06-30 | 2014-11-26 | Neos Therapeutics Lp | MISS-BROKEN MEDICINAL PRODUCTS |
| US10420729B2 (en) | 2013-03-15 | 2019-09-24 | R.P. Scherer Technologies, Llc | Abuse resistant capsule |
-
2014
- 2014-03-11 US US14/204,259 patent/US10420729B2/en active Active
- 2014-03-14 EP EP14711201.5A patent/EP2968129B1/en active Active
- 2014-03-14 EP EP20216392.9A patent/EP3824878A1/en active Pending
- 2014-03-14 CA CA2902501A patent/CA2902501C/en active Active
- 2014-03-14 DK DK14711201.5T patent/DK2968129T3/en active
- 2014-03-14 WO PCT/EP2014/055045 patent/WO2014140231A1/en active Application Filing
- 2014-03-14 HU HUE14711201A patent/HUE040530T2/hu unknown
- 2014-03-14 AR ARP140101047A patent/AR095343A1/es not_active Application Discontinuation
- 2014-03-14 CN CN201480014915.6A patent/CN105358132B/zh active Active
- 2014-03-14 PT PT14711201T patent/PT2968129T/pt unknown
- 2014-03-14 AU AU2014230481A patent/AU2014230481B2/en not_active Ceased
- 2014-03-14 MX MX2015012742A patent/MX2015012742A/es active IP Right Grant
- 2014-03-14 MX MX2020009411A patent/MX2020009411A/es unknown
- 2014-03-14 EP EP18190832.8A patent/EP3446681B1/en active Active
- 2014-03-14 ES ES14711201T patent/ES2700517T3/es active Active
- 2014-03-14 JP JP2015562169A patent/JP6395734B2/ja active Active
- 2014-03-14 CN CN201910975199.2A patent/CN110585165B/zh active Active
- 2014-03-14 SI SI201430988T patent/SI2968129T1/sl unknown
-
2016
- 2016-09-06 US US15/257,274 patent/US10744097B2/en active Active
-
2018
- 2018-08-09 AU AU2018214110A patent/AU2018214110B2/en not_active Ceased
- 2018-08-28 JP JP2018159092A patent/JP6820117B2/ja active Active
- 2018-12-03 CY CY181101283T patent/CY1120959T1/el unknown
-
2019
- 2019-09-16 US US16/572,148 patent/US11464747B2/en active Active
- 2019-11-15 AU AU2019264648A patent/AU2019264648B2/en not_active Ceased
-
2020
- 2020-12-29 JP JP2020219732A patent/JP2021073196A/ja active Pending
-
2022
- 2022-07-19 US US17/813,517 patent/US20220362160A1/en active Pending
- 2022-12-09 JP JP2022197405A patent/JP2023051939A/ja active Pending
Also Published As
Similar Documents
| Publication | Publication Date | Title |
|---|---|---|
| PT2968129T (pt) | Cápsula resistente ao abuso | |
| HRP20180684T1 (hr) | Kombinacija lijekova | |
| HK1219663A1 (zh) | 藥物組合 | |
| GB201309702D0 (en) | Security | |
| AU350563S (en) | A capsule | |
| GB2519319B (en) | Coffee capsule | |
| GB201412074D0 (en) | Kettle | |
| PT3077216T (pt) | Estrutura de segurança | |
| IL242777A (en) | Building system elements | |
| GB2537764B (en) | Tea capsule | |
| HK1215561A1 (zh) | 劑量膠囊 | |
| HU4337U (en) | Heat-printable security print-carrier | |
| AU347055S (en) | Jug | |
| GB2545569B (en) | Coffee capsule | |
| HU4589U (en) | Capsule | |
| GB201307672D0 (en) | Coffee capsule | |
| HUP1300177A2 (en) | Inter-rotatable puzzle | |
| GB201322806D0 (en) | Security | |
| GB201312557D0 (en) | Mobile-devices security | |
| GB201320786D0 (en) | Medicament | |
| GB201311531D0 (en) | Concept six | |
| GB201417087D0 (en) | No detials | |
| GB201311463D0 (en) | Concept Nine | |
| GB201311548D0 (en) | Concept four | |
| HK1175930A2 (en) | Cookware |